• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Genetic and antigenic characterization of influenza A(H3N2) virus after 13 consecutive years of influenza surveillance in Senegal, 20

tetano

Editor, Senior Moderator
J Med Virol


. 2024 Oct;96(10):e70010.
doi: 10.1002/jmv.70010. Genetic and antigenic characterization of influenza A(H3N2) virus after 13 consecutive years of influenza surveillance in Senegal, 2010-2022

Mamadou Malado Jallow[SUP] 1 [/SUP], Mamadou Aliou Barry[SUP] 2 [/SUP], Ndiendé Koba Ndiaye[SUP] 1 [/SUP], Cheikh Talibouya Touré[SUP] 1 [/SUP], Cheikh Talla[SUP] 2 [/SUP], Davy Kiori[SUP] 1 [/SUP], Samba Niang Sagne[SUP] 2 [/SUP], Sara Sy[SUP] 1 [/SUP], Deborah Goudiaby[SUP] 1 [/SUP], Mbayame Ndiaye Niang[SUP] 1 [/SUP], Moussa Moise Diagne[SUP] 1 [/SUP], Gamou Fall[SUP] 1 [/SUP], Cheikh Loucoubar[SUP] 2 [/SUP], Ndongo Dia[SUP] 1 [/SUP]



Affiliations
Abstract

Despite decades of influenza surveillance in many African countries, little is known about the evolutionary dynamics of seasonal influenza viruses. This study aimed to characterize the epidemiological, genetic and antigenic profiles of A/H3N2 viruses in Senegal from 2010 to 2022. A/H3N2 infection was confirmed using reverse transcription-polymerase chain reaction. Subsequently, a representative of A/H3N2 isolates was selected for genome sequencing. Predicted vaccine efficacy was measured using the Pepitope model. During the study period, 22638 samples were tested and influenza was detected in 31.8%, among which type A was confirmed in 78.1%. Of the Influenza A cases, the H3N2 subtype was detected in 29.8%, peaking at expected times during the rainy season. Genome sequencing of 123A/H3N2 isolates yielded 24 complete and 99 partial genomic sequences. Phylogenetic analysis revealed the circulation of multiple clades of A/H3N2 in Senegal, including 2a.3, 3C.2 and 3C.3a. A/H3N2 isolates were mainly susceptible to the influenza antiviral drugs oseltamivir and zanamivir, but the primary adamantine-resistance marker, S31N was encountered in all isolates. At least nine potential N-linked glycosylation sites were predicted among A/H3N2 strains, six of which (at positions 24, 38, 79, 181, 262 and 301) remains conserved among all isolates. Antigenic distances between circulating strains and vaccine viruses indicated varying vaccine efficacies, from suboptimal to moderate protection. The findings emphasize the need to enhance local genomic and antigenic surveillance and further research on influenza epidemiology and genetic evolution in sub-Saharan Africa.

Keywords: Senegal; antigenic; characterization; genetic; influenza H3N2 virus; surveillance.

 
Back
Top Bottom